Hi!

This is a friendly reminder if you have anything you wish to communicate or disseminate, I’m here to assist you! 😊

I work at the Communications Department at the university and I am the advisor for the Faculty of Medicine. With a background in journalism, my job is to highlight the exciting and important research happening here.

I can assist with:

• Professional communication advice and coaching
• Press releases
• Video
• Help with writing debate posts
• Media outreach
• Conducting interviews about your research for the website or forskning.no

You can also reach out to one of my colleagues at the faculty who works with communication:

• Marion Solheim (marion.solheim@uib.no)
• Ingrid Hagerup (ingrid.hagerup@uib.no)

The call aims to support and enable transnational collaboration between clinical research environments on investigator-initiated clinical trials.

Projects applying for funding must:

1. Be randomized pragmatic comparative effectiveness studies;
2. Compare the use of current approved interventions, either with each other or with standard practice;
3. Include interventions that may encompass, but are not limited to: diagnostic, screening, prevention, and treatment interventions. The interventions may, but are not limited to, pharmacological and non-pharmacological procedures such as nutrition and/or lifestyle interventions, surgery, prognostic methods, medical devices, e-health, and digital interventions;
4. Address one or more of the following diseases (or related comorbidities): cardiovascular diseases, metabolic disorders, nutrition and lifestyle-related diseases, and non-communicable respiratory diseases.

   Amound contributed by the Resarch Council: NOK 10 million

– Open for application: November 20, 2024
– Sketch deadline: January 28, 2025, at 00:00 CET

 https://www.forskningsradet.no/utlysninger/internasjonale-fellesutlysninger/pragmatiske-sammenlignende-effektstudier-ikke-smittsomme-sykdommer/

Input Meeting:

• November 4th. 11:30 AM – 12:30 PM Digital

For the ten portfolio boards appointed at the beginning of 2024, work is now underway on new portfolio plans. We invite you to provide input on the draft portfolio plan for Groundbreaking Research. The meeting is for representatives from research institutions in the institute and university sectors.

The portfolio plans are governance documents that aim to provide predictability for both applicants and funding ministries. They are brief and overarching and are concretized in an investment plan that is updated annually.

In the meeting, the goals, priorities, and measures in the draft portfolio plan will be reviewed.

Link:

• https://www.forskningsradet.no/arrangementer/2024/innspelsmote-portefoljeplan-banebrytande-forsking/

Dear member

We are excited to invite you and your colleagues to join InLifeScience 2024, our annual conference happening on October 30th at Forskningsparken. This year’s event will gather professionals from across the life science industry to discuss innovation, growth, and opportunities for collaboration, with a focus on shaping the future of life sciences together. You can explore the full program and register here.

As a valued member of The Life Science Cluster, you and your colleagues can attend at a reduced admission fee of 1000 NOK. We encourage you to share this invitation with your team so they can take advantage of this opportunity as well.

If you have any questions or need assistance, feel free to reach out. We look forward to seeing you and your team at InLifeScience 2024!

Best regards,
Benjamin Dyhre
Event and Communications Coordinator
The Life Science Cluster
+47 47 63 03 81
benjamin@tlsc.no

The regional cooperation body for research and innovation decided in its meeting on November 24, 2023, to strengthen the monitoring service. New is that the offer is now extended to include clinical studies that are not subject to mandatory monitoring. It is now possible to order monitoring of studies with increased risk.

Monitoring of clinical studies ensures that they are conducted, documented, and reported in accordance with the protocol, GCP, regulatory requirements, and relevant legislation. Monitoring is mandatory in drug studies and studies on medical devices that are to be CE marked. For other interventional studies, monitoring is optional. Experience from the Norwait study suggests that more studies than today should be monitored.

All health trusts in Helse Vest can report the need for monitoring. A form has been prepared as a guide for the trusts’ assessment of whether monitoring should be carried out. The completed form with relevant study documents is received by the monitoring service, which then assesses whether the study meets the criteria for the new scheme. Studies will be prioritized in case of high demand. A monitoring plan tailored to the individual study will then be prepared.

There is no co-payment for monitoring under this scheme.

Links:

• Kvalitetssikring av kliniske studier (monitorering)
• Søk om monitorering (Forms-skjema)
• Se også NorCRIN-rutiner